Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer
作者： Zacharenia Saridaki , John Souglakos
DOI: 10.1007/978-1-4614-7654-2_6
关键词:
摘要: Several studies have shown that mutation profiles could influence the treatment decisions in patients with metastatic colorectal cancer (mCRC). It has been proven mutations exon 2 of KRAS ongogene gain no benefit from monoclonal antibodies (moAbs) against Epidermal Growth Factor Receptor (EGFR), cetuximab and panitumumab. Currently, determination mutational status represents a paradigm for biomarkers development era molecular targeted therapies. The current manuscript is an overview, which summarizes critically reviews clinical relevance proposed mechanism resistance to beyond mutations, such as: outside codon 12 13, NRAS, BRAF V600E, PIK3CA 9 20 PTEN loss, EGFR ligands AREG, EREG mRNA expression amplification. aim identify markers might be used select higher probability response anti-EGFR moAbs. Overall, accumulating evidence biology CRC has, substantially, changed approach mCRC given clinicians more rational options treating this illness.
springer.com
sci-hub.st 参考文章(59)
Pablo Rodriguez-Viciana, Patricia H. Warne, Ritu Dhand, Bart Vanhaesebroeck, Ivan Gout, Michael J. Fry, Michael D. Waterfield, Julian Downward, PHOSPHATIDYLINOSITOL-3-OH KINASE AS A DIRECT TARGET OF RAS Nature. ,vol. 370, pp. 527- 532 ,(1994) , 10.1038/370527A0
C H Köhne, P Schöffski, H Wilke, C Käufer, R Andreesen, U Ohl, U Klaasen, M Westerhausen, W Hiddemann, G Schott, A Harstick, J Bade, A Horster, U Schubert, H Hecker, B Dörken, H J Schmoll, Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. Journal of Clinical Oncology. ,vol. 16, pp. 418- 426 ,(1998) , 10.1200/JCO.1998.16.2.418
C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, L. M. Amzel, The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations Science. ,vol. 318, pp. 1744- 1748 ,(2007) , 10.1126/SCIENCE.1150799
J Souglakos, J Philips, R Wang, S Marwah, M Silver, M Tzardi, J Silver, S Ogino, S Hooshmand, E Kwak, E Freed, J A Meyerhardt, Z Saridaki, V Georgoulias, D Finkelstein, C S Fuchs, M H Kulke, R A Shivdasani, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. British Journal of Cancer. ,vol. 101, pp. 465- 472 ,(2009) , 10.1038/SJ.BJC.6605164
Loredana Vecchione, Bart Jacobs, Nicola Normanno, Fortunato Ciardiello, Sabine Tejpar, EGFR-targeted therapy Experimental Cell Research. ,vol. 317, pp. 2765- 2771 ,(2011) , 10.1016/J.YEXCR.2011.08.021
James A. McCubrey, Melissa L. Sokolosky, Brian D. Lehmann, Jackson R. Taylor, Patrick M. Navolanic, William H. Chappell, Stephen L. Abrams, Kristin M. Stadelman, Ellis W.T. Wong, Negin Misaghian, Stefan Horn, Jörg Bäsecke, Massimo Libra, Franca Stivala, Giovanni Ligresti, Agostino Tafuri, Michele Milella, Marek Zarzycki, Andrzej Dzugaj, Francesca Chiarini, Camilla Evangelisti, Alberto M. Martelli, David M. Terrian, Richard A. Franklin, Linda S. Steelman, ALTERATION OF AKT ACTIVITY INCREASES CHEMOTHERAPEUTIC DRUG AND HORMONAL RESISTANCE IN BREAST CANCER YET CONFERS AN ACHILLES HEEL BY SENSITIZATION TO TARGETED THERAPY Advances in Enzyme Regulation. ,vol. 48, pp. 113- 135 ,(2008) , 10.1016/J.ADVENZREG.2008.02.006
Harith Rajagopalan, Alberto Bardelli, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. ,vol. 418, pp. 934- 934 ,(2002) , 10.1038/418934A
Carla Oliveira, Mafalda Pinto, Alex Duval, Caroline Brennetot, Enric Domingo, Eloi Espín, Manel Armengol, Hiroyuki Yamamoto, Richard Hamelin, Raquel Seruca, Simó Schwartz, BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene. ,vol. 22, pp. 9192- 9196 ,(2003) , 10.1038/SJ.ONC.1207061
L. Zhao, P. K. Vogt, Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 2652- 2657 ,(2008) , 10.1073/PNAS.0712169105
Hans Prenen, Sabine Tejpar, Eric Van Cutsem, Impact of molecular markers on treatment selection in advanced colorectal cancer European Journal of Cancer. ,vol. 45, pp. 70- 78 ,(2009) , 10.1016/S0959-8049(09)70018-8